



GENOMICS | CELL & GENE THERAPIES | BIOPRODUCTION

Genomic Vision at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels from 25 to 26 October 2023

- *Genomic Vision will present its innovative solutions and introduce its new HexaCard[®] service at the 30th Annual ESGCT Congress in Brussels.*
- *HexaCard[®] service enables the simultaneous analysis of six critical parameters to streamline cell line development, enhance productivity, and reduce costs.*
- *Participation in the ESGCT Congress enables Genomic Vision to introduce its advanced technology to the European pharmaceutical market, fostering collaborations and industry advancements.*

Bagneux (France) - Genomic Vision (FR0011799907 – GV, – the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of transformed cells is pleased to announce its participation in the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels, where GV will present its work in bioproduction and introduce its recently launched HexaCard[®] service.

Since the summer launch of HexaCard[®], Genomic Vision has witnessed significant interest from industrial players. This new service, designed to revolutionize cell line development, allows the simultaneous analysis of six key parameters, creating a unique identity card for each cell. This comprehensive analysis ensures the selection of the most suitable clones, thereby enhancing productivity and stability while reducing timelines and costs.

The HexaCard[®] service is poised to be a game-changer for the bioproduction industry, as it empowers pharmaceutical and biotech companies to streamline their cell line development processes. By providing a comprehensive characterization of transformed cells in a single assay, HexaCard[®] facilitates quicker and more cost-effective decision-making. It offers a level of precision that was previously unattainable, making it an invaluable asset for those involved in bioproduction and gene and cell therapy.

Genomic Vision's presence at the 30th Annual ESGCT Congress underscores its commitment to introducing this transformative technology to the European pharmaceutical and biotech markets. The

company looks forward to engaging with industry professionals, sharing insights, and building collaborations during the event, and contribute to the advancement of gene therapy, cell therapy, and bioproduction on a global scale. This congress serves as a valuable opportunity for Genomic Vision to engage with peers, foster collaborations, and ultimately drive innovation in the field.

Prakhar Bisht, PhD, Principal Scientist at Genomic Vision, shared his insights on this breakthrough service, saying, "Our presence at the ESGCT congress not only delineates our commitment to support Biomanufacturing and Cell & Gene therapy, but also to introduce our HexaCard® platform for services to a wider audience. Our presence at this congress allows us to share our cutting edge solutions with fellow experts and industry leaders."

ABOUT THE 30TH ANNUAL EUROPEAN SOCIETY OF CELL AND GENE THERAPY (ESGCT) CONGRESS

The 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress, hosted in Brussels from 24 to 27 October 2023, serves as a pivotal gathering for professionals in the field of gene and cell therapy. This prestigious event brings together scientists, researchers, industry leaders, and academia, providing an ideal platform for the exchange of knowledge and the exploration of cutting-edge innovations in the sector. With a focus on the latest advancements in gene and cell therapy, the ESGCT Congress provides a unique opportunity for attendees to stay at the forefront of industry developments and establish collaborations that drive progress in the field.

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services for the highly accurate characterization of genome modifications. We deliver high-quality integrated genomic analysis solutions to improve quality control and bioproduction standards of advanced gene therapies at scale. Based on molecular combing technology and artificial intelligence, The Company provides robust quantitative measurements needed for high confidence characterization of transformed cell lines and prediction of cell line performance, in particular in the context of the biomanufacturing processes of cell and gene therapies. Genomic Vision's molecular combing technology has further applications in drug development of agents targeting DNA replication and damage response mechanisms, visualizing DNA replication kinetics and telomere length maintenance. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

CONTACTS

Genomic Vision
Aaron Bensimon
Chairman of the Management Board
Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com

NewCap
France Investor Relations
& Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu



Member of the CAC[®] Mid & Small and CAC[®] All-Tradable indices

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Risk Factors" section of the universal registration document filed with the AMF on April 28, 2023 under number D.23-0383, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Genomic Vision has set up a financing line in the form of convertible notes with warrants (OCABSA) with its Financing partner.

The shares resulting from the conversion or exercise of the aforementioned securities will, in general, be sold on the market, which could create downward pressure on the share price as well as a dilution.

Shareholders could therefore suffer a loss of their invested capital due to a significant decrease in the value of the company's shares. The company has carried out several dilutive financing operations, and investors are advised to be very careful before making a decision to invest in the company's securities.